BIOREXIS
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
BIOREXIS
Industry:
Health Care Insurance Therapeutics
Founded:
2001-08-01
Address:
United, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
38 M USD
Current Advisors List
Founder
Investors List
Prism Venture Management
Prism Venture Management investment in Series B - BioRexis
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series B - BioRexis
Anthem Capital Management
Anthem Capital Management investment in Series B - BioRexis
Quaker BioVentures
Quaker BioVentures investment in Series B - BioRexis
Tullis Health Investors
Tullis Health Investors investment in Series B - BioRexis
ProQuest Investments
ProQuest Investments investment in Series B - BioRexis
Gund Investment, LLC
Gund Investment, LLC investment in Series B - BioRexis
ProQuest Investments
ProQuest Investments investment in Series A - BioRexis
Quaker BioVentures
Quaker BioVentures investment in Series A - BioRexis
Tullis Health Investors
Tullis Health Investors investment in Series A - BioRexis
More informations about "BioRexis"
Pfizer to acquire privately-held BioRexis | Reuters
Pfizer Inc <PFE.N> said it agreed to acquire privately held BioRexis Pharmaceutical Corp. for an undisclosed amount to access new technology and potential product candidates for diabetes.See details»
Pfizer to Acquire BioRexis to Access Novel Technology Platform …
Feb 5, 2007 BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with substantially longer duration of …See details»
BioRexis Pharmaceutical - PitchBook
BioRexis Pharmaceutical was acquired on 01-Feb-2007. Who acquired BioRexis Pharmaceutical? BioRexis Pharmaceutical was acquired by Pfizer. Data Transparency. Meet our data hygiene …See details»
Press Release: Pfizer To Acquire BioRexis Pharmaceutical
Feb 1, 2007 Pfizer To Acquire BioRexis Pharmaceutical Corporation To Access Novel Technology Platform And Early Stage Diabetes Pipeline NEW YORK, Feb. 1 -- Pfizer Inc …See details»
BioRexis - Funding, Financials, Valuation & Investors - Crunchbase
Oncology Therapeutics Network provides integrated solutions primarily related to healthcare and insurance.See details»
BioRexis - Drug pipelines, Patents, Clinical trials - Synapse
Explore BioRexis with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Pfizer to Acquire BioRexis Pharmaceutical - BioPharm International
Feb 23, 2007 Pfizer Inc. (New York, NY, www.pfizer.com) will acquire BioRexis Pharmaceutical (Pennsylvania, PA, www.biorexis.com) Corporation, a privately-held biopharmaceutical …See details»
BioRexis Pharmaceutical LLC - Company Profile and News
Company profile page for BioRexis Pharmaceutical LLC including stock price, company news, executives, board members, and contact informationSee details»
Pfizer buys BioRexis to access novel protein technology
Feb 2, 2007 BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with substantially longer duration of …See details»
Drawn to diabetes tech, Pfizer inks deal for BioRexis
Jan 31, 2007 Pfizer is buying BioRexis Pharmaceutical for an undisclosed amount. BioRexis uses protein engineering technology in its work developing new therapies for diabetes. The …See details»
Pfizer To Acquire BioRexis To Access Novel Technology Platform …
Acquisition is a Further Step in Pfizer Strategy to Accelerate Business Development and Licensing Activity. New York - Pfizer Inc announced that it has entered into an agreement to …See details»
BioRexis Pharmaceutical - Overview, News & Similar companies
BioRexis developed and solely owns this technology, which gives it great flexibility in transactions with pharmaceutical companies. Read More. View Company Info for Free. Who is BioRexis …See details»
BioRexis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Oncology Therapeutics Network provides integrated solutions primarily related to healthcare and insurance.See details»
BioRexis Pharmaceutical Corp. - Scrip
Jun 1, 2004 BioRexis Pharmaceutical hopes to solve the problems with protein drugs by exploiting a previously overlooked human protein as a novel protein fusion scaffold. If the …See details»
BioRexis - Contacts, Employees, Board Members, Advisors & Alumni
Oncology Therapeutics Network provides integrated solutions primarily related to healthcare and insurance.See details»
Research programme: GLP-1 fusion peptide - BioRexis
BioRexis Pharmaceutical Corporation is developing GLP-1 fusion peptide [GLP-1-Tf, BRX0585] for the treatment of type 2 diabetes.BioRexis' proprietary Engineered ... If your organization …See details»
Respironics - Crunchbase Company Profile & Funding
BioRexis is a biopharmaceutical company. It develops and produces biopharmaceuticals. BioRexis offers protein and peptide drugs with pharmacology and trans-bodies to replace …See details»
Research programme: erythropoietin mimetics - BioRexis
BioRexis Pharmaceutical Corporation is developing a peptide mimetic of erythropoietin [EPO mimetic - BioRexis] using its proprietary fusion technology platformSee details»
Biolexis
Dr. David J. Bearss is a trendsetting entrepreneur of drug development with over 20 years’ of experience. Not only is David an industry-leading expert in small molecule drug development …See details»